KLK3 and pure red-cell aplasia: The current gold-standard biomarker for non-invasive PrCa detection is prostate-specific antigen (PSA), which has high sensitivity but is known to suffer from low specificity (Thompson et al., 2004; Mistry and Cable, 2003).